Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Related Keywords

China , Minnesota , United States , Suzhou , Jiangsu , Jiaotong , Guizhou , Xianqun , Qinghai , Shanghai , American , Chinese , Alia Teprotumumab , Eli Lilly , Innovent Biologics , Adimab Incyte , Group Of Oculoplastic , Group Of Thyroid Diseases , Md Anderson Cancer Center , Clinical Development Of Innovent , American Thyroid Society , Prnewswire Innovent Biologics Inc , Chinese Ophthalmology Branch , Chinese Academy Of Engineering , Chinese Medical Association , American Thyroid Association , Development Of Medicines , Chinese Endocrinology Branch , China National Drug Administration , Linkedin , Shanghai Jiaotong University School Of Medicine , European Group On Grave , European Group On Grave Orbitopathy , European Thyroid Society , European Thyroid Association , New Drug Application , Drug Evaluation , Thyroid Eye Disease , Xianqun Fan , Chinese Academy , Shanghai Ninth People , Shanghai Jiaotong University School , Lei Qian , Vice President , Clinical Development , Chinese Clinical Diagnosis , Treatment Guidelines , European Group , European Thyroid , Curr Opin , Olmsted Country , Trans Am Ophthalmol Soc , Retrieved June , Medscape Reference , Active Thyroid Eye Disease , Pract Res Clin Endocrinol , Grave Orbitopathy , Orbital Diseases , Thyroid Diseases , Chinese Medical , Chinese Guidelines , Thyroid Associated Ophthalmopathy , Chinese Journal , Consensus Statement , Eur Thyroid ,